209 related articles for article (PubMed ID: 32682539)
1. Hepatitis B virus - recent therapeutic advances and challenges to cure.
Mouzannar K; Liang TJ
J Hepatol; 2020 Sep; 73(3):694-695. PubMed ID: 32682539
[No Abstract] [Full Text] [Related]
2. [Discussions the therapy strategy of chronic hepatitis B by analyzing the therapeutics course of a chronic hepatitis B patient].
Yang LQ
Zhonghua Gan Zang Bing Za Zhi; 2009 Sep; 17(9):709-10. PubMed ID: 19785967
[No Abstract] [Full Text] [Related]
3. [Bringing the antiviral therapy home for chronic hepatitis B patients: host immunity influences the efficacy and disease prognosis].
Wang FS; Zhang JY
Zhonghua Gan Zang Bing Za Zhi; 2009 Mar; 17(3):164-6. PubMed ID: 19554778
[No Abstract] [Full Text] [Related]
4. HBV Chronic hepatitis during chemotherapy - an immune controlled disease.
Caruntu FA; Gheorghita V
J Gastrointestin Liver Dis; 2008 Dec; 17(4):445-9. PubMed ID: 19104707
[No Abstract] [Full Text] [Related]
5. Update on hepatitis B virus infection.
You CR; Lee SW; Jang JW; Yoon SK
World J Gastroenterol; 2014 Oct; 20(37):13293-305. PubMed ID: 25309066
[TBL] [Abstract][Full Text] [Related]
6. Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B.
Su TH; Hsu CS; Chen CL; Liu CH; Huang YW; Tseng TC; Liu CJ; Chen PJ; Lai MY; Chen DS; Kao JH
Antivir Ther; 2010; 15(8):1133-9. PubMed ID: 21149920
[TBL] [Abstract][Full Text] [Related]
7. Early serum hepatitis B virus large surface protein level: a stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B.
Zhu X; Gong Q; Yu D; Zhang D; Gu L; Han Y; Chen J; Zhang Y; Zhang X
J Clin Virol; 2013 Aug; 57(4):318-22. PubMed ID: 23639294
[TBL] [Abstract][Full Text] [Related]
8. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference
Cornberg M; Lok AS; Terrault NA; Zoulim F;
J Hepatol; 2020 Mar; 72(3):539-557. PubMed ID: 31730789
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B surface antigen monitoring and management of chronic hepatitis B.
Sonneveld MJ; Zoutendijk R; Janssen HL
J Viral Hepat; 2011 Jul; 18(7):449-57. PubMed ID: 21692954
[TBL] [Abstract][Full Text] [Related]
10. HBV cure: why, how, when?
Levrero M; Testoni B; Zoulim F
Curr Opin Virol; 2016 Jun; 18():135-43. PubMed ID: 27447092
[TBL] [Abstract][Full Text] [Related]
11. Meeting the Challenge of Eliminating Chronic Hepatitis B Infection.
Revill PA; Penicaud C; Brechot C; Zoulim F
Genes (Basel); 2019 Apr; 10(4):. PubMed ID: 30939846
[TBL] [Abstract][Full Text] [Related]
12. Recovery of circulating CD56
Liu N; Liu B; Zhang L; Li H; Chen Z; Luo A; Chen M; Peng M; Yin W; Ren H; Hu P
Int Immunopharmacol; 2018 Sep; 62():59-66. PubMed ID: 29990695
[TBL] [Abstract][Full Text] [Related]
13. Challenges to a Cure for HBV Infection.
Testoni B; Levrero M; Zoulim F
Semin Liver Dis; 2017 Aug; 37(3):231-242. PubMed ID: 28847034
[No Abstract] [Full Text] [Related]
14. Is there an association between the measurement of qualitative HBsAg and virologic response in chronic HBV infection?
Altinbas A; Aktas B; Basar O; Yüksel O; Ekiz F; Yilmaz B; Coban S
Ann Hepatol; 2012; 11(3):320-5. PubMed ID: 22481449
[TBL] [Abstract][Full Text] [Related]
15. Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B.
Chen Y; Li X; Ye B; Yang X; Wu W; Chen B; Pan X; Cao H; Li L
Antiviral Res; 2011 Jul; 91(1):23-31. PubMed ID: 21549152
[TBL] [Abstract][Full Text] [Related]
16. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B.
Tangkijvanich P; Komolmit P; Mahachai V; Sa-nguanmoo P; Theamboonlers A; Poovorawan Y
J Clin Virol; 2009 Oct; 46(2):117-23. PubMed ID: 19651540
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B surface antigen seroclearance in patients with chronic hepatitis B infection: a clinical study.
Ruan P; Xu SY; Zhou BP; Huang J; Gong ZJ
J Int Med Res; 2013 Oct; 41(5):1732-9. PubMed ID: 23908397
[TBL] [Abstract][Full Text] [Related]
18. Does hepatitis B surface antigen kinetics, including both decline and reaching a threshold, improve prediction of response?
Wiegand J; Patel K; Tillmann HL
Hepatology; 2009 Oct; 50(4):1314; author reply 1314. PubMed ID: 19676132
[No Abstract] [Full Text] [Related]
19. [Is quantification of HBsAg levels useful in the follow-up of patients with chronic hepatitis B virus infection?].
Romero M; Madejón A; García-Samaniego J
Gastroenterol Hepatol; 2014; 37(6):350-3. PubMed ID: 24698803
[No Abstract] [Full Text] [Related]
20. [Results of 2 years of interferon treatment in HBeAg positive chronic hepatitis B].
Hu LH; Long XZ; Tang CL
Zhonghua Gan Zang Bing Za Zhi; 2009 Dec; 17(12):940-1. PubMed ID: 20038338
[No Abstract] [Full Text] [Related]
[Next] [New Search]
